Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Inclusion Criteria: * Volunteers will be males or females 18-65 yrs of age with a diagnosis of schizophrenia or schizoaffective disorder who have a history of significant weight gain with olanzapine or clozapine administration. * Volunteers will have a current BMI=\>27 but equal to or less than 40. * Volunteers will have been taking a stable dose (less than 10% dose change) of clozapine or olanzapine or at least two months prior to study start. * Volunteers will be willing and able to participate in the subcutaneous administration training week prior to study start. * Able and willing to give informed consent. Exclusion Criteria: * Clinically significant abnormal pre-admission vital signs, positive HIV, or clinical laboratory evaluations, in which the principal investigator deems the subject-volunteer ineligible for the study * Positive results for infectious diseases and sexually-transmitted diseases will be reported according to the Texas Department of State Health and Texas Administrative Code rules and guidelines * Any patient with current diabetes mellitus, even if caused by antipsychotic use . * Patients with active liver disease requiring current treatment. Positive hepatitis C volunteers will only be excluded if they have active liver disease or they have enzyme values are two times the upper limit of normal. * Any patients with medical disorders that are not properly controlled by medications. * Pregnant women or women who are breast feeding. * Patients concomitantly treated with another conventional or second generation antipsychotic medication or with any other anti-obesity drug. * Mental capacity is limited to the extent that the patient cannot understand the nature of the study along with its risks and benefits. * Subjects with a high risk of suicide since there is a potential that the study medication will lower the subject's glucose levels. * Any patient judged by the principal investigator to be inappropriate for the study. * Known hypersensitivity to study medication or its components * Non-English speaking * The clinical assessments that will be used are not available in valid and reliable forms for non-English speaking populations.